Science Corporation raises $400 million to expand vision implant business
The brain technology start-up founded by former Neuralink president Max Hodak is now valued at $3.5 billion after a Series D round, and plans to seek US approval for its PRIMA vision implant.

Key takeaways
- Science Corporation raised a $400 million Series D and is valued at $3.5 billion, according to TechCrunch.
- Its PRIMA implant restores some vision in age-related macular degeneration and is approved in Europe and sold in Germany.
- The device is now being trialled for Stargardt's disease, Hodak announced at TechCrunch Disrupt.
- The company aims to enter the US market via the FDA's Humanitarian Device Exemption and is designing first human trials of a bio-hybrid brain sensor.
In this article
What happened
Science Corporation, a medical technology start-up founded in 2021 by former Neuralink president Max Hodak, has raised $400 million in a Series D round, according to TechCrunch. The company announced the raise in a blog post on 17 November 2026.
The funding values the company at $3.5 billion, a figure TechCrunch attributes to a person familiar with the deal.
The PRIMA vision implant
Science's first product is PRIMA, a chip that is partly worn outside the body and partly implanted, designed to restore some sight in people with age-related macular degeneration, a common eye condition that destroys central vision in older adults.
The device is already approved in Europe and is on the market in Germany. Hodak announced at TechCrunch Disrupt that PRIMA is now also being trialled for Stargardt's disease, a genetic condition that causes blindness.
Plans for the United States
The new money will help Science bring PRIMA to the United States. The company plans to use the FDA's Humanitarian Device Exemption, a regulatory route that allows experimental medical technology to be approved for rare conditions.
Science has persuaded the FDA that advanced macular degeneration affecting both eyes is uncommon enough to qualify for that pathway, according to TechCrunch. Approval is not yet granted, so US availability remains a plan rather than a fact.
The longer-term brain ambition
Hodak co-founded Science to use new technologies to understand and interact with the brain, and its founding goal goes beyond eyesight. The company is developing a bio-hybrid sensor, a device that combines cultured neurons, meaning living nerve cells grown in a lab, with silicon electronics, to connect directly to the human brain.
Science is designing the first human trials of that sensor with Murat Günel, a neurosurgery professor at Yale. Günel told TechCrunch the device could eventually offer potential treatments for Parkinson's disease and other brain injuries and illnesses. Those trials are still at the design stage, so any clinical benefit is unconfirmed.
Why it matters

A $3.5 billion valuation places Science among the better-funded neurotechnology companies challenging Neuralink, where Hodak once served as president. The raise signals continued investor appetite for brain-computer interfaces with a commercial product already on the market.
For patients, the near-term significance is practical: PRIMA is approved and sold in Europe, is being tested for a second condition, and could reach US patients through a rare-device pathway if regulators agree.
Sources
Spotted a mistake? See our corrections policy. Read how News by OnDevice works in our editorial policy.



